117 related articles for article (PubMed ID: 23649232)
1. Impact of hormone replacement therapy use on mammographic screening outcomes.
Beckmann KR; Farshid G; Roder DM; Hiller JE; Lynch JW
Cancer Causes Control; 2013 Jul; 24(7):1417-26. PubMed ID: 23649232
[TBL] [Abstract][Full Text] [Related]
2. The mammography screening detection of ductal carcinoma in situ and invasive breast cancer according to women's characteristics: is it the same?
Théberge I; Vandal N; Guertin MH; Perron L
Breast Cancer Res Treat; 2019 Apr; 174(2):525-535. PubMed ID: 30564969
[TBL] [Abstract][Full Text] [Related]
3. Trends in detection of invasive cancer and ductal carcinoma in situ at biennial screening mammography in Spain: a retrospective cohort study.
Román M; Rué M; Sala M; Ascunce N; Baré M; Baroja A; De la Vega M; Galcerán J; Natal C; Salas D; Sánchez-Jacob M; Zubizarreta R; Castells X;
PLoS One; 2013; 8(12):e83121. PubMed ID: 24376649
[TBL] [Abstract][Full Text] [Related]
4. Incidence of invasive breast cancer and ductal carcinoma in situ in a screening program by age: should older women continue screening?
Erbas B; Amos A; Fletcher A; Kavanagh AM; Gertig DM
Cancer Epidemiol Biomarkers Prev; 2004 Oct; 13(10):1569-73. PubMed ID: 15466971
[TBL] [Abstract][Full Text] [Related]
5. Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study.
Duffy SW; Dibden A; Michalopoulos D; Offman J; Parmar D; Jenkins J; Collins B; Robson T; Scorfield S; Green K; Hall C; Liao XH; Ryan M; Johnson F; Stevens G; Kearins O; Sellars S; Patnick J
Lancet Oncol; 2016 Jan; 17(1):109-14. PubMed ID: 26655422
[TBL] [Abstract][Full Text] [Related]
6. Hormone replacement therapy and mammographic screening outcomes in Western Australia.
Crouchley K; Wylie E; Khong E
J Med Screen; 2006; 13(2):93-7. PubMed ID: 16792833
[TBL] [Abstract][Full Text] [Related]
7. Hormone replacement therapy, percent mammographic density, and sensitivity of mammography.
Kavanagh AM; Cawson J; Byrnes GB; Giles GG; Marr G; Tong B; Gertig DM; Hopper JL
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1060-4. PubMed ID: 15894653
[TBL] [Abstract][Full Text] [Related]
8. Influence of patterns of hormone replacement therapy use and mammographic density on breast cancer detection.
Chiarelli AM; Kirsh VA; Klar NS; Shumak R; Jong R; Fishell E; Yaffe MJ; Boyd NF
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1856-62. PubMed ID: 17035392
[TBL] [Abstract][Full Text] [Related]
9. Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study.
Gapstur SM; Morrow M; Sellers TA
JAMA; 1999 Jun; 281(22):2091-7. PubMed ID: 10367819
[TBL] [Abstract][Full Text] [Related]
10. Hormone replacement therapy and accuracy of mammographic screening.
Kavanagh AM; Mitchell H; Giles GG
Lancet; 2000 Jan; 355(9200):270-4. PubMed ID: 10675074
[TBL] [Abstract][Full Text] [Related]
11. Integration of 3D digital mammography with tomosynthesis for population breast-cancer screening (STORM): a prospective comparison study.
Ciatto S; Houssami N; Bernardi D; Caumo F; Pellegrini M; Brunelli S; Tuttobene P; Bricolo P; Fantò C; Valentini M; Montemezzi S; Macaskill P
Lancet Oncol; 2013 Jun; 14(7):583-9. PubMed ID: 23623721
[TBL] [Abstract][Full Text] [Related]
12. Rapid increase in incidence of breast ductal carcinoma in situ in Girona, Spain 1983-2007.
Puig-Vives M; Pollan M; Rue M; Osca-Gelis G; Saez M; Izquierdo A; Marcos-Gragera R
Breast; 2012 Oct; 21(5):646-51. PubMed ID: 22340960
[TBL] [Abstract][Full Text] [Related]
13. Screening mammography use among current, former, and never hormone therapy users may not explain recent declines in breast cancer incidence.
Buist DS; Walker R; Bowles EJ; Carney PA; Taplin SH; Onega T; Kerlikowske K; Clinton W; Miglioretti DL
Cancer Epidemiol Biomarkers Prev; 2012 May; 21(5):720-7. PubMed ID: 22301831
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer in Singapore: some perspectives.
Jara-Lazaro AR; Thilagaratnam S; Tan PH
Breast Cancer; 2010; 17(1):23-8. PubMed ID: 19701678
[TBL] [Abstract][Full Text] [Related]
15. Trends in incidence of ductal carcinoma in situ: the effect of a population-based screening programme.
Sørum R; Hofvind S; Skaane P; Haldorsen T
Breast; 2010 Dec; 19(6):499-505. PubMed ID: 21071225
[TBL] [Abstract][Full Text] [Related]
16. Mammographic density and risk of second breast cancer after ductal carcinoma in situ.
Habel LA; Capra AM; Achacoso NS; Janga A; Acton L; Puligandla B; Quesenberry CP
Cancer Epidemiol Biomarkers Prev; 2010 Oct; 19(10):2488-95. PubMed ID: 20929881
[TBL] [Abstract][Full Text] [Related]
17. Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study.
Partridge A; Adloff K; Blood E; Dees EC; Kaelin C; Golshan M; Ligibel J; de Moor JS; Weeks J; Emmons K; Winer E
J Natl Cancer Inst; 2008 Feb; 100(4):243-51. PubMed ID: 18270338
[TBL] [Abstract][Full Text] [Related]
18. Overdiagnosis among women attending a population-based mammography screening program.
Falk RS; Hofvind S; Skaane P; Haldorsen T
Int J Cancer; 2013 Aug; 133(3):705-12. PubMed ID: 23355313
[TBL] [Abstract][Full Text] [Related]
19. Digital mammography screening: association between detection rate and nuclear grade of ductal carcinoma in situ.
Weigel S; Heindel W; Heidinger O; Berkemeyer S; Hense HW
Radiology; 2014 Apr; 271(1):38-44. PubMed ID: 24475843
[TBL] [Abstract][Full Text] [Related]
20. Pathologic findings from the Breast Cancer Surveillance Consortium: population-based outcomes in women undergoing biopsy after screening mammography.
Weaver DL; Rosenberg RD; Barlow WE; Ichikawa L; Carney PA; Kerlikowske K; Buist DS; Geller BM; Key CR; Maygarden SJ; Ballard-Barbash R
Cancer; 2006 Feb; 106(4):732-42. PubMed ID: 16411214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
